Psychiatry/Psychology | Phase I Developments | JAPAN

Astellas Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062

Lead Product(s): ASP8062

Therapeutic Area: Psychiatry/Psychology Product Name: ASP8062

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 22, 2020

Details:

This NIH grant will help fund Astellas's two phase 1 clinical studies to evaluate the safety and efficacy of ASP8062, an oral small molecule GABAB receptor Positive Allosteric Modulator (PAM), as an add-on maintenance therapy for Opioid Use Disorder (OUD).

Sumitomo Dainippon Pharma Co., Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Sumitomo Dainippon, Exscientia begin study of AI based OCD drug

Lead Product(s): DSP-1181

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

DSP-1181 is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist, and its phase I clinical study to treat obsessive-compulsive disorder as an indication candidate.

Sumitomo Dainippon Pharma Co., Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Stu...

Lead Product(s): DSP-1181

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Through this deal, Sumitomo Dainippon Pharma has expanded its development pipeline to treat key unmet medical needs in the Psychiatry and Neurology area.

Find

Find Psychiatry/Psychology Drugs in Phase I Clinical Development in JAPAN

Japan

Product Type

Companies

Astellas Pharma

Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062

Sumitomo Dainippon Pharma Co., Ltd

Sumitomo Dainippon, Exscientia begin study of AI based OCD drug

Sumitomo Dainippon Pharma Co., Ltd

Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Stu...